Albany, New York, January 12, 2018: Cardiovascular diseases are the most important cause of death all over the world. Millions of people die every year due to heart attacks and stroke. About 25% of all Americans have one or more types of cardiovascular disease. The major ones are coronary, artheroclerosis, angina, congenital and arrhythmia. Looking at the rising prevalence, there has been vast scientific innovation in the cardiovascular disease drugs therapeutics market in recent decades. To explore further, a study titled “Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape” has been publicized to the online repository of Market Research Hub. The study recognizes the leading therapeutics, as well as gaps in the market, with portfolios of key marketed products, including historical and forecast sales revenue patterns.

Research Enclosures

In this study, active clinical trials for the CVD treatment are also briefly explained. Through this analysis, the research presents predictions that how can pipeline innovations change the CVD market in the near future. As per the report, the CVD market landscape is forecast to undergo a period of substantial change due to key approvals, patent expiries and acquisitions. In addition, the research also considers market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.

In the first part, a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment is provided. Furthermore, for the benefit of the readers, the research also predicts that how the growing treatment landscape will drive market growth to 2023 and understand the contributions that different products and companies will make to this growth. Which of the leading companies will have the highest market share by 2023? Strategies that have major companies adopted to achieve market growth is also mentioned in an important section of competitive landscape.

Findings from the study

It has been analyzed that most critical risk factors for CVD include hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque buildup within blood vessels. Dyslipidemia and hypertension have continuing high levels of development within the current pipeline. The report adds that the treatments usually fall within three categories: Anti-hypertensives, which aim to maintain blood pressure within a normal range; anti-dyslipidemic drugs, which aim to modify lipid levels to a normal range; and anti-thrombotic drugs, which aim to prevent thrombi formation by inhibiting the coagulation cascade.

The current pipeline includes nearly 200 products for the treatment of heart failure, suggesting an increase in interest in treating the disease. According to the report, new products for deep vein thrombosis, pulmonary arterial hypertension and dyslipidemia to shake-up the competitive landscape.

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.